Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$595.73 USD

595.73
733,122

+5.74 (0.97%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $595.76 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline

IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.

McKesson (MCK) Hits 52-Week High, Can the Run Continue?

McKesson (MCK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Abbott (ABT) Scales to a 52-Week High: What's Driving It?

Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.

LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout

LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.

Here's Why You Should Hold on to Integra (IART) Stock for Now

Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.

Are These Medical Stocks Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

BD (BDX) Partners With Retailers for At-Home COVID-19 Test

BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.

Thermo Fisher (TMO) Releases New Update for Omicron Detection

Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.

Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM

CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.

Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.

Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M

Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Accuray's (ARAY) CyberKnife System Gets Shonin Approval

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Are Investors Undervaluing These Medical Stocks Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here's Why You Should Retain Ecolab (ECL) Stock Right Now

Ecolab (ECL) continues to gain traction from a solid product portfolio and segmental strength. However, segmental weakness remains a woe.

Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering

Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.